SeaStar Medical to Present at Upcoming Biotech Showcase 2026 Investor Conference
Rhea-AI Summary
SeaStar Medical (Nasdaq: ICU) announced that CEO Eric Schlorff will present at the Biotech Showcase 2026 investor conference at the Hilton Union Square in San Francisco on January 13, 2026 at 3:00 p.m. Pacific Standard Time. The presentation will be streamed live on the company website and a replay will be posted at approximately 6:00 p.m. PST on January 13, 2026 and remain available for up to 30 days after posting.
SeaStar management will also meet with investors in San Francisco during the 44th Annual J.P. Morgan Healthcare Conference from January 12–14, 2026.
Positive
- None.
Negative
- None.
News Market Reaction 2 Alerts
On the day this news was published, ICU declined 0.39%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $42K from the company's valuation, bringing the market cap to $11M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ICU was down 1.56% pre-news. Peers showed mixed moves, e.g., AKTX -6.6%, BOLD -4.07%, while NRXS and RNTX were modestly positive, suggesting stock-specific rather than coordinated sector trading.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 23 | Reverse stock split | Negative | -8.6% | Announced 1-for-10 reverse split to address Nasdaq minimum bid requirement. |
| Dec 02 | Regulatory update | Positive | +8.3% | FDA allowed SAVE registry enrollment reduction for QUELIMMUNE pediatric AKI surveillance. |
| Nov 20 | Investor conference | Neutral | -0.4% | CEO scheduled presentation at NobleCon21 with replay available for 30 days. |
| Nov 17 | Management change | Positive | -20.3% | Appointment of experienced healthcare CFO Michael Messinger to support growth. |
| Nov 13 | Earnings and updates | Neutral | -7.8% | Q3 2025 results plus QUELIMMUNE commercial data and NEUTRALIZE-AKI trial progress. |
Recent history shows mixed reactions: clearly positive regulatory progress saw gains, while capital-structure and leadership changes often coincided with declines.
Over the last few months, ICU navigated capital-structure changes, regulatory progress, and leadership updates. A 1-for-10 reverse split effective in early Jan 2026 followed shareholder approvals aimed at maintaining Nasdaq listing. In Dec 2025, FDA approval to cut SAVE registry enrollment from 300 to 50 patients for QUELIMMUNE post-approval monitoring coincided with a positive price reaction. Management strengthened its finance function with a new CFO and continued reporting early QUELIMMUNE commercialization and trial progress, although those updates were followed by share price declines. Today’s conference appearance fits within this ongoing investor outreach.
Market Pulse Summary
This announcement highlights SeaStar Medical’s effort to maintain investor visibility through the Biotech Showcase 2026 and meetings around the 44th Annual J.P. Morgan Healthcare Conference. Against a backdrop of recent reverse-split approval, FDA flexibility on the SAVE registry, and early QUELIMMUNE commercialization, investors may focus on how management communicates commercial traction, clinical progress, and funding plans. Key metrics to monitor include future regulatory updates, revenue trends, and any additional capital-raising activity disclosed in filings.
AI-generated analysis. Not financial advice.
DENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at the Biotech Showcase 2026 Investor Conference at the Hilton Union Square, San Francisco, CA, on January 13, 2026, at 3:00 p.m. Pacific Standard Time.
The live presentation will be available on the Company's website and can be accessed here. A replay of the presentation will be available at approximately 6:00 p.m. Pacific Standard Time on January 13, 2026, and can be accessed here. The replay will be available for up to 30 days following its posting.
Additionally, SeaStar Medical’s management team will be meeting with investors in San Francisco during the 44th Annual J.P. Morgan Healthcare Conference from January 12-14, 2026.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The QUELIMMUNE (SCD-PED) therapy is SeaStar Medical’s first commercial product based on its patented Selective Cytopheretic Device (SCD) technology. The QUELIMMUNE (SCD-PED) therapy was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Contact:
SeaStar Investor Relations:
IR@SeaStarMed.com
FAQ
When will SeaStar Medical (ICU) present at Biotech Showcase 2026?
How can investors watch SeaStar Medical (ICU) live at Biotech Showcase 2026?
Will SeaStar Medical (ICU) provide a replay of the Biotech Showcase presentation?
Is SeaStar Medical (ICU) meeting investors at the J.P. Morgan Healthcare Conference?
Where can I find SeaStar Medical (ICU) presentation materials or replay after the event?
What time will the SeaStar Medical (ICU) replay be available on January 13, 2026?
